New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis

  • Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
  • 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
  • New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
/by
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
arcticnovartis

  • Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer
  • Kisqali® NATALEE oral presentation to report prognostic and predictive impact of gene expression from largest biomarker CDK4/6i trial dataset
  • Scemblix® ASC4FIRST oral presentation to feature longer-term 144-week efficacy, safety and tolerability data in first-line Ph+ CML-CP
/by
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
arcticnovartis

  • More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone
  • Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks
  • sNDA filed in US, China and Japan; decisions expected H2 2026
/by
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
arcticnovartis

  • US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast–to–coast RLT manufacturing network – the largest in the US
  • Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
  • Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing
/by
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis

  • At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients
  • New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therape

/by
Novartis partners with Special Olympics World Winter Games Switzerland 2029

Novartis partners with Special Olympics World Winter Games Switzerland 2029
angilma1

/by
Full Circle: A Story of Growth, Purpose and Coming Home to Novartis

Full Circle: A Story of Growth, Purpose and Coming Home to Novartis
tavasat1

/by
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR
   
Erstes Quartal

/by
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

First quarter

/by
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 
arcticnovartis

  • Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1
  • Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment2
/by